Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Poster presentation

Lymphoid chemokine expression in Sjogren's syndrome: relationship with the lymphoid organization of the periductal inflammatory aggregates

Authors: F Barone, M Bombardieri, MC Blades, A Manzo, P Morgan, S Challacombe, G Valesini, C Pitzalis

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

The inflammatory cellular infiltrate typical of several chronic diseases, including Sjogren syndrome (SS), is often organized in lymphoid-like structures. CXCL13 and CCL21 are lymphoid chemokines critical for physiologic development of secondary lymphoid organs. They have also been implicated in the formation of ectopic lymphoid neogenesis in various experimental and pathological conditions. To define the relationship between the in situ production of CXCL13 and CCL21 and lymphoid organization in SS we examined the expression of these chemokines in relation to the degree of B-cell and T-cell segregation, the presence of follicular dendritic cell (FDC) (CD21+) networks and germinal centre (GC) reactions as well as the development of high endothelial venule (HEV) (PNAd+)-like vessels. …
Metadata
Title
Lymphoid chemokine expression in Sjogren's syndrome: relationship with the lymphoid organization of the periductal inflammatory aggregates
Authors
F Barone
M Bombardieri
MC Blades
A Manzo
P Morgan
S Challacombe
G Valesini
C Pitzalis
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1409

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine